In a prostate cancer preclinical model, transferrin-conjugated PLGA NPs with encapsulated paclitaxel displayed better anti-tumor activity than either free paclitaxel or NPs with paclitaxel that did not have the transferrin conjugation. This evidence concerns the gene TF and prostate cancer.